VCAM
TCRT icon

Van Cleef Asset Management’s Alaunos Therapeutics TCRT Stock Holding History

Van Cleef Asset Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-96
Closed -$1.02K – 116
2023
Q4 		$1.02K Hold
96
– – ﹤0.01% 111
2023
Q3 		$1.9K Buy
+96
New +$4.14K ﹤0.01% 107

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Van Cleef Asset Management's TCRT Position: Q1 2024 in Review

Van Cleef Asset Management sold out of Alaunos Therapeutics (TCRT) in Q1 2024, closing a stake of 96 shares — an estimated $1.02K sold.

Van Cleef Asset Management first reported a position in TCRT in Q3 2023 and held it in 2 quarters. The position peaked at $1.9K in Q3 2023. 45 funds tracked by Wall St. Rank hold TCRT as of Q1 2024.

  • Van Cleef Asset Management reported no remaining Alaunos Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Van Cleef Asset Management sold 96 Alaunos Therapeutics shares in Q1 2024, an estimated $1.02K.
  • Van Cleef Asset Management first reported a position in Alaunos Therapeutics in Q3 2023 and held it in 2 quarters.
  • Van Cleef Asset Management's Alaunos Therapeutics position peaked at $1.9K in Q3 2023.
  • 45 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2024.

Based on Van Cleef Asset Management's 13F filing for Q1 2024, filed 10 May 2024.